| 发明名称 | PAR-1 antagonists for use in the treatment or prevention of influenza virus type A infections | ||
| 摘要 | The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist. | ||
| 申请公布号 | US8802623(B2) | 申请公布日期 | 2014.08.12 |
| 申请号 | US201013508301 | 申请日期 | 2010.11.15 |
| 申请人 | Institut National de la Recherche Agronomique | 发明人 | Riteau Béatrice;Khoufache Khaled |
| 分类号 | A61K31/517;A61K38/04;A61K39/42;A61P31/16;A61K38/00;C07K7/06;C07K14/005 | 主分类号 | A61K31/517 |
| 代理机构 | McAndrews, Held & Malloy Ltd. | 代理人 | McAndrews, Held & Malloy Ltd. |
| 主权项 | 1. A method of treating an influenza virus type A infection which comprises administration of a therapeutically effective amount of at least one Protease-Activated Receptor-1 (PAR-1) antagonist to a subject, wherein said at least one PAR-1 antagonist is N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine. | ||
| 地址 | Paris FR | ||